BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical- stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non- executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive emp ...